CDKN2B and neoplasm: Inhibition of DNMT1 by DNMT inhibitors as a class of drugs that target the epigenetic regulators and other approaches, such as antisense oligonucleotide, reduces the DNA methylation level and reactivates expression of tumor suppressors such as p16ink4A and/or p15ink4B [6,7].